H.R. 7909, Medicare Expansion and Drug Price Negotiation. Quorum's AI analysis reads it as a net benefit — and names who gains.
H.R. 7909 · Net good
What it does
This bill expands Medicare to allow people aged 50–64 to buy into the program, adds a new direct supplemental insurance option to cover cost-sharing, authorizes the federal government to negotiate drug prices with pharmaceutical manufacturers on behalf of Medicare beneficiaries, establishes a reinsurance fund to stabilize individual health insurance markets, and increases the income threshold for premium tax credits under the Affordable Care Act. The bill aims to lower out-of-pocket costs and expand coverage for hearing, dental, and vision care.
The analysis names Medicare beneficiaries aged 50–64 (lower premiums and expanded coverage) — and 3 more groups — among the beneficiaries.
The trade-off
The Medicare buy-in premium is set to be budget-neutral (expenditures not increased by reason of this section), meaning premiums may be higher than traditional Medicare to offset federal costs. Enrollees aged 50–64 may face higher premiums than they expect if adverse selection occurs.
Transparency scores 65%. The analysis flags 1 rider and a high warning level.
Who is behind it
Filed by Raja Krishnamoorthi.